Center for Cancer & Immunology Research
About the Lab
The Cruz Laboratory aims to develop novel innate- and adaptive-immune, cell-based therapies for human immunodeficiency virus (HIV) and cancer, using several technologies, including gene modification, cell expansion and bioengineering.
Engineered antigen-specific T cells secreting broadly neutralizing antibodies: Combining innate and adaptive immune response against HIVPowell AB, Ren Y, Korom M, Saunders D, Hanley PJ, Goldstein H, Nixon DF, Bollard CM, Lynch RM, Jones RB, Cruz CRY PMID: 33005704; PMCID: PMC7508916 Mol Ther Methods Clin Dev 21;19:78-88. DOI: 10.1016/j.omtm.2020.08.015 August (2020)
A new method for reactivating and expanding T cells specific for Rhizopus oryzaeCastillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CR PMCID: PMC6054701 Mol Ther Methods Clin Dev 9: 305-312 (2018)
Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patientsMcCormack SE, Cruz CRY, Wright KE, Powell AB, Lang H, Trimble C, Keller MD, Fuchs E, Bollard CM PMID: 29331266 Cytotherapy 20(3):385-393 March (2018)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 studyCruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G Erratum in: Blood. 2014 May 22;123(21):3364. PMCID: PMC3811171. Blood 122(17):2965-73 October (2013)
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text. PMCID: PMC3218253. Clin Cancer Res. 17(22):7058-66. November (2011)